Prostate Cancer Update 2

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of- the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest, either current or within the past 12 months, for themselves (or their spouses/partners) that have been resolved through a peer review process: John Brebner, Anne Jacobson, MPH, Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Chris Thomson, MD, MS, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Crawford — Professor of Surgery and Radiation Oncology; Head, Urologic Oncology, University of Colorado Health Sciences Center, Aurora, Colorado. Fees For Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, GPC Biotech, Sanofi-Aventis. Dr Freedland — Attending Physician, Durham VA Medical Center; Assistant Professor of Urology and Pathology, Duke University School of Medicine, Durham, North Carolina. Consulting Fees and Contracted Research: AstraZeneca Pharmaceuticals LP, GTx Inc; Fees For Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP. Dr Gomella — The Bernard W Godwin Professor of Prostate Cancer; Chairman, Department of Urology, Jefferson Medical College; Director of Urologic Oncology, Kimmel Cancer Center, Philadelphia, Pennsylvania. Consulting Fees and Contracted Research: GlaxoSmithKline; Fees For Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP. Dr Keane — Chairman and Professor, Medical University of South Carolina, Department of Urology, Charleston, South Carolina. Consulting Fees and Contracted Research: AstraZeneca Pharmaceuticals LP, Cytogen Corporation, Indevus Pharmaceuticals Inc; Fees For Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Cytogen Corporation, Sanofi-Aventis. Dr Moul — Professor and Chief, Division of Urologic Surgery, Duke University Medical Center, Durham, North Carolina. Consulting Fees: AstraZeneca Pharmaceuticals LP; Contracted Research: GlaxoSmithKline; Fees for Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Sanofi-Aventis; Ownership Interest: Theralogix LLC. Dr Roach — Professor, Radiation Oncology and Urology; Chairman, Department of Radiation Oncology, UCSF Comprehensive Cancer Center, San Francisco, California. Consulting Fees and Contracted Research: AstraZeneca Pharmaceuticals LP, Siemens AG, TAP Pharmaceuticals Inc. Dr Taplin — Assistant Professor of Medicine, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Consulting Fees and Contracted Research: Genentech BioOncology, GTx Inc, Novartis Pharmaceuticals Corporation; Fees For Non-CME Services Received Directly from Commercial Interest or Their Agents: AstraZeneca Pharmaceuticals LP. Dr Zelefsky — Chief, Brachytherapy Service, Memorial Sloan-Kettering Cancer Center, New York, New York. No financial interests or affiliations to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.